Status:
TERMINATED
AIH Risk Stratification With Multiparametric MRI
Lead Sponsor:
Perspectum
Conditions:
Autoimmune Hepatitis
Eligibility:
All Genders
18+ years
Brief Summary
The primary aim of this study is to investigate whether the baseline cT1 can predict those whose condition relapses following treatment withdrawal. The secondary aim is to investigate correlation of ...
Detailed Description
Patients with AIH who have been undergoing immunosuppressive treatment for 18-24 months will be invited for a series of multiparametric MRI (mpMRI) scans to assess the utility of LMS for monitoring ch...
Eligibility Criteria
Inclusion
- Patients undergoing management for AIH being considered for treatment cessation
- Patients diagnosed with AIH, are treatment naïve, and will be undergoing biopsy as per clinical pathway
- Diagnostic biopsy prior to cessation of treatment (where possible)
- 18+ years of age.
- Ability to give informed consent
Exclusion
- Any contraindication to MRI scanning
- Any clinically significant medical or psychiatric condition
Key Trial Info
Start Date :
October 20 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 15 2023
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT04339621
Start Date
October 20 2020
End Date
April 15 2023
Last Update
November 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Touchstone Medical Imaging
Fort Worth, Texas, United States, 76104